Skip to main content
. Author manuscript; available in PMC: 2020 Aug 1.
Published in final edited form as: Am J Kidney Dis. 2019 Feb 23;74(2):213–223. doi: 10.1053/j.ajkd.2018.12.037

Figure 3. Change in vascular endothelial cell protein expression with spironolactone and placebo.

Figure 3.

Vascular endothelial cell protein expression of nuclear factor κ B (NFκB; n=20 spironolactone; n=14 placebo; Panel A), interleukin 6 (IL-6; n=20 spironolactone; n=13 placebo; Panel B), NADPH oxidase (n=20 spironolactone; n=13 placebo; Panel C), and phosphorylated endothelial nitric oxide synthase (PeNOS; n=12 spironolactone; n=10 placebo; Panel D) at baseline (black bars) and following 24 weeks of treatment (white bars) with spironolactone or placebo. Expression is relative to human umbilical vein endothelial cell (HUVEC) control. Representative images shown below. Date are mean±s.e.